The U.S. Food and Drug Administration (FDA) has agreed to review Pharming’s application to get Ruconest (conestat alfa) approved for the routine prevention of swelling attacks caused by hereditary angioedema (HAE). The therapy already is approved for the acute treatment of swelling attacks in adults and adolescents with…
News
Recent Posts
- Treatment may help keep HAE attacks away for years, study finds
- Longer gaps between HAE treatment injections may be possible, study finds
- Experimental oral treatment quickly controls HAE attacks in Phase 3 trial
- Kid-friendly Orladeyo ‘sprinkles’ now FDA-approved for older HAE patients
- A hereditary angioedema diagnosis can be spooky